Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R11.htm
EX-3.1 - Q Therapeutics, Inc.ex3-1.htm
EX-3.2 - Q Therapeutics, Inc.ex3-2.htm
EX-32.1 - Q Therapeutics, Inc.ex32-1.htm
EX-32.2 - Q Therapeutics, Inc.ex32-2.htm
EX-14.1 - Q Therapeutics, Inc.ex14-1.htm
EX-31.2 - Q Therapeutics, Inc.ex31-2.htm
EX-31.1 - Q Therapeutics, Inc.ex31-1.htm
10-Q - Q Therapeutics, Inc.form10q.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R15.htm
v2.4.0.6
Organization and Summary of Significant Accounting Policies (Details Narrative) (USD $)
9 Months Ended
Sep. 30, 2012
Jun. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Mar. 28, 2002
Organization And Summary Of Significant Accounting Policies          
Percentage of acquisition         100.00%
Common stock issued for merger per share         2.1633835
Percentage of shares issued and outstanding by Q Therapeutics stockholders         89.70%
Deficit accumulated during the development stage $ 19,241,506     $ 17,434,438  
Private placement of common stock, gross   $ 4,018,047      
Anti dilutive losses 15,072,509   8,379,779